# Post-COVID-19 Inflammatory Arthritis Treated With Upadacitinib: A Case Report

## TL;DR

This case report shows that upadacitinib effectively treats inflammatory arthritis that occurs after a COVID-19 infection.

## Contribution

The report demonstrates the clinical effectiveness of upadacitinib in treating post-COVID-19 inflammatory arthritis.

## Key findings

- Two patients with post-COVID-19 inflammatory arthritis showed meaningful clinical improvement with upadacitinib.
- Upadacitinib was associated with reduced inflammation markers and symptom relief in treated patients.

## Abstract

Two patients who developed inflammatory arthritis following COVID-19 infection are presented, characterized by arthralgias, arthritis, and elevated markers of inflammation (C-reactive protein). Both patients had clinically meaningful responses to treatment with upadacitinib, a Janus Kinase inhibitor (JAKi). This case report highlights the efficacy and safety of upadacitinib in the treatment of post-COVID-19 inflammatory arthritis.